Trends in Cancer

Article	Citations
Subscription & copyright page	296
Revumenib: a new era in acute leukemia treatment	283
Advancements in organoid models emulating metastatic niches	270
Engineering growth factor ligands and receptors for therapeutic innovation	254
Pseudomyxoma peritonei and the microbiome: Emerging observations and unanswered questions	234
FBXW10: a male-biased E3 ligase in liver cancer	234
An immunological panacea for cancer-related cachexia	223
Platelets: tailoring metastasis treatment	213
Targeting solid tumor antigens with chimeric receptors: cancer biology meets synthetic immunology	200
Spliced to kill: RNA mis-splicing derived cancer neoantigens	197
Cancer evolution: from Darwin to the Extended Evolutionary Synthesis	176
Clinical perspective and treatment of immune-related colitis after cancer immunotherapy	174
Tumor-resident microbes: the new kids on the microenvironment block	172
Navigating life as an early career researcher	162
Subscription & copyright page	157
Advisory Board and Contents	156
Leveraging circulating microbial DNA for early cancer detection	149
Onco-condensates: formation, multi-component organization, and biological functions	127
Under pressure: clonal hematopoiesis in patients receiving cancer therapy	126
Accessing the vasculature in cancer: revising an old hallmark	121
Engine shutdown: migrastatic strategies and prevention of metastases	118
Circulating tumor DNA in biliary tract cancers: challenges, opportunities, and clinical readiness	115
The evolving landscape of brain metastasis: volume II	114
Regulation of metastatic organotropism	111
Subscription & copyright page	110

GOT2 consider the tumor microenvironment	109
Molecular insights into SMARCA2 degradation in SMARCA4-mutant lung cancers	108
cGAS–STING and the deadly CIN: how chronic inflammation represents a therapeutic vulnerability in chromosomally unstable cancers	106
Oncogenic competence: balancing mutations, cellular state, and microenvironment	99
FGFR rearrangements: oncogenic drivers and therapeutic targets	87
Benefits and opportunities of the transgenic Oncopig cancer model	85
Mitochondrial transfer reveals an organellar layer of cancer ecology	84
Recent developments in myeloid immune modulation in cancer therapy	82
From prediction to precision: how immunopeptidomics advances neoantigen discovery	82
Nonrepair functions of DNA mismatch repair proteins: new avenues for precision oncology	81
Neural hijacking in cancer metabolism: from nutrients to organelles	80
Diet, nutrient supply, and tumor immune responses	74
Chromatin as an old and new anticancer target	74
Advancements in combining targeted therapy and immunotherapy for colorectal cancer	72
Crosstalk of T cells within the ovarian cancer microenvironment	71
Cell death, therapeutics, and the immune response in cancer	70
Targeting the Hippo pathway in cancer: kidney toxicity as a class effect of TEAD inhibitors?	70
Gut microbiota – a double-edged sword in cancer immunotherapy	70
Cancer immunotherapeutic challenges from autophagy-immune checkpoint reciprocal regulation	69
Subscription & copyright page	69
Advisory Board and Contents	69
Toward mutational epidemiology: using mutational signatures of environmental exposures to assess cancer risk	69
Palmitate paves the way to lung metastasis	65
Horizontal mitochondrial transfer and the tug-of-war between cancer cells and immune cells	64
Organellar pH as an emerging vulnerability to exploit in cancer	63
Planning for cancer: building accessible and high-quality survivorship care for all	63
Genetic immune escape in cancer: timing and implications for treatment	62
Neural checkpoint therapy in lung cancer	62
Clinical and translational relevance of intratumor heterogeneity	60
Scaling data toward pan-cancer foundation models	60
Inflammation: the incubator of the tumor microenvironment	58
Subscription & copyright page	56
The emerging field of oncolytic virus-based cancer immunotherapy	56
Advisory Board and Contents	54
Advisory Board and Contents	53
Advisory Board and Contents	53
Advancing cancer precision surgery with the tumor coagulome	52
Molecular and clinical insights into early-onset endometrial cancer	52
Advisory Board and Contents	52
Emerging mechanisms of telomerase reactivation in cancer	52
Microbiome: a driver of pancreatic inflammation and tumorigenesis	51
Gut microbial metabolites for potentiating cancer therapy	51
Updating cancer research with patient-focused networks	51
RHOA takes the RHOad less traveled to cancer	50
Prospects for understanding and exploiting the consequences of hyperactivation lethality	49
Stress granules and hormetic adaptation of cancer	49
Endogenous and imposed determinants of apoptotic vulnerabilities in cancer	49
Circulating cell-free DNA-based multi-cancer early detection	49
TRANSCLINSCI_COL	49
Gastric cancer immunosuppressive microenvironment heterogeneity: implications for therapy development	48

A novel mechanism of autophagy-dependent immunosuppression in cancer?	48
Cuproptosis in cancer: from molecular mechanisms to therapeutic intervention	48
B7-H3: a robust target for immunotherapy in prostate cancer	48
Transcriptional regulation of hypoxic cancer cell metabolism and artificial intelligence	47
Advisory Board and Contents	46
Advisory Board and Contents	46
A macrophage-neutrophil program drives mammary carcinogenesis	45
Subscription & copyright page	44
Advisory Board and Contents	43
Advisory Board and Contents	43
Mechanistic cancer prevention comes of age	43
Subscription & copyright page	42
The evolving posology and administration of immune checkpoint inhibitors: subcutaneous formulations	42
RNA vaccines for cancer: revolutionizing immunization strategies	40
Beyond safety: suicide systems in cell-based cancer therapies	40
Leveraging space innovations for cancer breakthroughs on Earth	40
Orchestrating tumor-immune epigenetics via SERT–H3Q5ser axis	39
Metabolism and epigenetics: drivers of tumor cell plasticity and treatment outcomes	38
Branched chain amino acids and their aberrant metabolism in cancer	38
The promise of TIL therapy for glioblastoma	38
Targeting TIM-3 to halt lung precancer progression	38
CAR T cell persistence in cancer	37
Time-of-day dependency of adoptive cell therapies	37
Neoantigen-directed therapeutics in the clinic: where are we?	36
Advisory Board and Contents	35
Subscription & copyright page	35
Ferroptosis vulnerability in FLT3-mutant leukemia	35
Functional heterogeneity of fibroblasts in primary tumors and metastases	35
Advisory Board and Contents	34
Advisory Board and Contents	34
Space in cancer biology: its role and implications	34
Neural circuits in lung adenocarcinoma modulate immunosurveillance	33
Advisory Board and Contents	32
Targeting myeloid cells for cancer immunotherapy: Siglec-7/9/10/15 and their ligands	32
Clonal evolution and hierarchy in myeloid malignancies	32
ApCAFs: spatial niches and therapeutic insights across cancers	32
Dissecting histological transformation	31
Tumor-draining lymph nodes – friend or foe during immune checkpoint therapy?	31
Addressing the genetic/nongenetic duality in cancer with systems biology	30
Dying to survive: harnessing inflammatory cell death for better immunotherapy	30
Engineered bacterial therapeutics for detecting and treating CRC	30
Subscription & copyright page	29
IL-33 and ILC2 in pancreatic cancer: good, bad or a bit of both?	29
Genitourinary cancer neoadjuvant therapies: current and future approaches	28
The development of therapy related myeloid neoplasms in childhood cancer survivors	28
Mapping heterogeneity in the tumor microenvironment of renal cell carcinoma through single-cell omics	28
Lifileucel: the first cellular therapy approved for solid tumours	27
Using Drosophila to uncover the role of organismal physiology and the tumor microenvironment in cancer	27
In vivo macrophage engineering as novel therapeutic strategy against liver metastasis	27
Epigenetic reprogramming in pediatric gliomas: from molecular mechanisms to therapeutic implications	26
Mesothelioma: a systemic therapy clinical trials snapshot	26
A new enhancer for anti-PD-1/PD-L1 immunotherapy: PCSK9 inhibition	26
NETscape or NEThance: tailoring anti-cancer therapy	26
Subscription & copyright page	26
Next-generation cancer vaccines and emerging immunotherapy combinations	26
Immunomodulation by endothelial cells: prospects for cancer therapy	26
Successfully targeting the cancer system with metronomics for medulloblastoma	26
Advisory Board and Contents	25
Subscription & copyright page	25
IGSF3-mediated potassium dysregulation promotes neuronal hyperexcitability and glioma progression	24
Embracing diversity: macrophage complexity in cancer	24
Deciphering the roles of ABCB5 in normal and cancer cells	23
The extracellular matrix in cancer: from understanding to targeting	22
Persisting cancer cells are different from bacterial persisters	22
How DNA methylation predicts response to cancer therapies	22
Circulating extracellular vesicles and tumor cells: sticky partners in metastasis	21
Emerging and extensive clonal evolution in the pancreas	21
CRISPR tools for T cells: targeting the genome, epigenome, and transcriptome	21
Bone marrow microenvironment: roles and therapeutic implications in obesity-associated cancer	21
Self-reactive, innate-like T cells enhance cytotoxicity and immunosurveillance	21
Future perspectives on engineered T cells for cancer	21
Towards enhancing the predictive value of the microbiota for cancer immunotherapy	21
Enhancing dendritic cells by inhibiting BCL2	21
Subscription & copyright page	21
How cancer cells make and respond to interferon-I	21
Fueling the revolution: RIBOTACs manipulating RNA decay	21
Hypoxia orchestrates the lymphovascular–immune ensemble in cancer	20
Advancing human leukocyte antigen-based cancer immunotherapy: from personalized to broad-spectrum strategies for genetically heterogeneous populations	20
Think zebras: challenges and opportunities for treating rare cancers	20
Acetylation: a new target for protein degradation in cancer	20

Small cell lung cancer profiling: an updated synthesis of subtypes, vulnerabilities, and plasticity	20
Defining obesity in the context of cancer: thinking beyond body mass index	20
TET2, tumor control, and CAR T cell hyperproliferation	20
Extracellular vesicle lipids in cancer immunoevasion	19
Tackling the next decade of cancer research	19
Navigating the biophysical landscape: how physical cues steer the journey of bone metastatic tumor cells	19
Subscription & copyright page	19
The clinical landscape of CAR-engineered unconventional T cells	19
Interferon epsilon and ovarian cancer	19
The redox paradox in HGGs: ROS as drivers and destroyers	19
Current landscape of CD3 bispecific antibodies in hematologic malignancies	19
Poised epigenetic states dictate metastatic fitness	19
Watching cancer begin: emerging tools to visualize the first steps of tumorigenesis	19
Dynamic immune signatures as biomarkers for irAEs	19
A growing entourage for heterotypic circulating tumor cell clusters	18
Intracranial CAR-T cell delivery in glioblastoma patients	18
ALPK1 agonists ignite innate immunity in anticancer therapy	18
Time to heal: inhibiting fibrosis prevents glioblastoma recurrence	18
Regulated cell death modalities: breaking resistance of temozolomide glioblastoma therapy	17
Tissue mechanics in tumor heterogeneity and aggression	17
Intratumoral immune cell manipulations as a strategy to enhance cancer vaccine efficiency	17
Mechanisms of T cell exhaustion guiding next-generation immunotherapy	17
The tumor-draining lymph node as a reservoir for systemic immune surveillance	17
Limited dsRNA editing impedes leukemia stem cells	17
Advisory Board and Contents	16
mtDNA transfer from senescent cancer cells to MDSCs promotes immunosuppression	16
Advisory Board and Contents	16
A biopsychosocial model to understand racial disparities in the era of cancer immunotherapy	16
Targeting phagocytosis to enhance antitumor immunity	16
Wargaming cancer: a strategy for future precision oncology?	16
Defying inflammation-driven early-onset colorectal cancer: predict, prevent, and personalize	16
KRAS inhibitors: resistance drivers and combinatorial strategies	15
Spatially resolving cancer: from cell states to therapy	15
Adaptive inhibition of CGAS signaling by TREX1	15
Reductive stress in cancer: coming out of the shadows	15
Subscription & copyright page	15
Lifestyle and host determinants of antitumor immunity and cancer health disparities	15
Spatial promoter–enhancer hubs in cancer: organization, regulation, and function	15
Harnessing FLASH irradiation to improve immunotherapy of medulloblastoma	15
Ancestry-defined molecular taxonomy of prostate cancer	14
Label-free optical imaging for brain cancer assessment	14
Subscription & copyright page	14
Lost but not least: Y chromosome loss as a driver of cancer	14
Many faces, many places: delving deeper into CAF heterogeneity in NSCLC	14
Polo-like kinases as immune modulators: a new frontier in cancer immunotherapy	14
Targeting cyclin-dependent kinases in cancer: emerging therapeutics and clinical strategies	13
Into the era of mycobiome-driven cancer research	13
Drug independence and the curability of cancer by combination chemotherapy	13
Advances in targeting RNA modifications for anticancer therapy	13
The peritumor microenvironment: physics and immunity	13
Subscription & copyright page	13
The emerging roles of the urea cycle in tumor microenvironment and therapies	13
Myeloid cell path to malignancy: insights into liver cancer	13
Subscription & copyright page	13
Advisory Board and Contents	13
Exclusion of immune cells by vascular gates	13
Impact of tissue-agnostic approvals on management of primary brain tumors	13
Leveraging immunologically based therapies to treat diffuse large B-cell lymphoma	12
Metabolic landscape of disseminated cancer dormancy	12
Aging: Barrier or catalyst of cancer?	12
Epigenetic control of immunoevasion in cancer stem cells	12
Immunometabolism of CD8+ T cell differentiation in cancer	12
Advisory Board and Contents	12
Immune organoids: from tumor modeling to precision oncology	12
Neuro-immune interactions and immuno-oncology	11
The future of cancer research: invest now	11
Advisory Board and Contents	11
γδT cells and breast cancer: wicked allies	11
Emerging roles of nucleotide metabolism in cancer	11
Subscription and copyright page	11
Cancer fitness genes: emerging therapeutic targets for metastasis	11
Host and microbiome lipid metabolism in colorectal cancer development and therapy	11
Advisory Board and Contents	11
Treatment of patients with pMMR GI cancers with tumor-infiltrating lymphocytes (TIL): a reality?	11
Disarming cancer resistance: FAK as a therapeutic target	11
Immune cells in residual disease and recurrence	10
Targeting cancer stem cells in multiple myeloma	9
Targeting vulnerabilities of aneuploid cells for cancer therapy	9
CD4+ T cells in antitumor immunity	9
Therapeutic targeting of regulatory T cells in cancer	9
EZHIP’s role in diffuse midline glioma: echoes of oncohistones?	9
CX3CL1: a key switch of cell death immunogenicity	9
Small molecules targeting microRNAs: new opportunities and challenges in precision cancer therapy	9
Immune mechanisms of toxicity from checkpoint inhibitors	9
Trends in cancer imaging	9
Generation of tumor neoantigens by RNA splicing perturbation	9
Neuronal and tumourigenic boundaries of glioblastoma plasticity	9
Plastic persisters: revival stem cells in colorectal cancer	9
Decoding endoplasmic reticulum stress signals in cancer cells and antitumor immunity	8
A new BRAF inhibitor breaks resistance barriers	8
Immune vulnerabilities of mutant KRAS in pancreatic cancer	8
Evolution of first versus next-line targeted therapies for metastatic non-small cell lung cancer	8
A lysosomal requiem for glioblastoma cells	8
Subscription &copyright page	8
The urgent need to improve childhood cancer cachexia	8